MMJ BioScience Proceeding with FDA Multiple Sclerosis Clinical Trial of Medicinal Cannabis 2018

While a growing number of states have legalized marijuana for medical use, medical marijuana differs from pharmaceutical treatments in that even state to state legal forms are not FDA regulated.

MMJ International Holdings, the premier medical cannabis research company that is advancing the science of medical marijuana through patient clinical research and the operation of medical cannabis healthcare businesses, announced that its affiliate MMJ Bioscience has engaged Bianca Weinstock-Guttman, MD, as their principal investigator. Dr. Bianca Weinstock-Guttman is a Professor of Neurology at the State University of New York in Buffalo and serves as Executive Director of the New York State Multiple Sclerosis Consortium. She will execute the FDA approved study exploring the potential therapeutic applications of cannabinoids for progressive multiple sclerosis patients.

MMJ BioScience’s first clinical trial of cannabis-based medicines involving patients suffering from Multiple Sclerosis and its related forms of severe pain and spasticity will be seeking FDA permission to proceed to undertake a pharmaceutical research study to develop a prescription cannabis-based medicine. MMJ BioScience will commence their Phase 2 clinical trials with the guidance of their clinical research organization Parexel.

Michael Sharpe, spokesman for MMJ BioScience, said, “Entering Phase 2 trials is a highly significant point in the development of our cannabis-based medicines. These trials will allow us to demonstrate efficacy in a limited number of subjects and to establish the necessary dosage regimen and delivery mechanisms to provide the most effective relief to sufferers from the acute pain and spasticity associated with MS.”

The trials, to be conducted at a number of…

Article Source…

Leave a Reply

Your email address will not be published. Required fields are marked *